Dr Marmé is co-chair of the AGO Study Group and member of the Scientific Board of the German Breast Group (GBG). His translational research is focused on the exploitation of DNA damage repair and synthetic lethality in gynaecological malignancies, the modulation of the tumour-microenvironment and patient-derived 3D cell culture models, all of which are investigated as part of the AGO-OVAR 27 study. He has led numerous trials as national and international Coordinating Investigator, and is the international Principal Investigator of the phase III GBG102/SASCIA study, investigating sacituzumab govitecan in post-neoadjuvant HER2-negative breast cancer.

Dr Marmé has authored numerous papers published in peer-reviewed international journals and has been an invited speaker at several international meetings. He has also collaborated on various international publications (books) as an author and editor and serves as an Associate Editor for Cancer Investigation journal. Dr Marmé has served as a member of the European Society of Medical Oncology (ESMO) Faculty group for gynaecologic cancers since 2021 and has been a member of the Scientific Committee for several ESMO congresses and meetings. He has joined the ESMO Educational Publications Working Group in January 2024.